ENVERIC BIOSCIENCES, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
ENVERIC BIOSCIENCES, INC. (ENVB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $202.15 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-28
- ENVERIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $202.15K, a 56.41% decline from fiscal 2023.
- ENVERIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $463.70K, a 82.73% decline from fiscal 2022.
- ENVERIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $2.68M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2024-12-31 | $202.15K 10-K · filed 2025-03-28 |
| 2023-12-31 | $463.70K 10-K · filed 2025-03-28 |
| 2022-12-31 | $2.68M 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |